Effects of teriparatide in postmenopausal women with osteoporosis pre-treated with bisphosphonates: 36-month results from the European Forsteo Observational Study.

ABSTRACT:

Objectives

To describe fracture rates, back pain, and health-related quality of life (HRQoL) in postmenopausal women with osteoporosis and prior bisphosphonate therapy, treated with teriparatide for up to 18 months and followed up for a further 18 months.

Design

Prospective, multinational, and observational study.

Methods

Data on prior bisphosphonate use, clinical fractures, back pain visual analog scale (VAS), and HRQoL (EQ-5D) were collected over 36 months. Fracture data were summarized in 6-month intervals and analyzed using logistic regression with repeated measures. Changes from baseline in back pain VAS and EQ-VAS were analyzed using a repeated measures model.

Results

Of the 1581 enrolled patients with follow-up data, 1161 (73.4%) had a history of prior b

SUBMITTER: Jakob F 

PROVIDER: S-EPMC3232638 | biostudies-literature | 2012 Jan

REPOSITORIES: biostudies-literature